Mercedes-Benz will launch three new SUVs in South Korea in September and October to meet rising demand and cement its status as a leader in the country's imported car market.
The three all-new SUV models are the Mercedes-Benz GLB, the Mercedes-Benz GLA, and the Mercedes-Benz GLE Coupe.
The three SUV models went on sale in Europe last year.
The addition of the three models will increase the number of Mercedes-Benz Korea's SUVs to nine.
Mercedes-Benz Korea will start selling the GLA and GLB models in September followed by the GLE Coupe model in October.
The prices range from 54 million won to 119 million won.
In recent years, Mercedes-Benz has been leading other imported vehicle brands in South Korea, helped by a growing appetite for premium vehicles and German brands among Korean consumers.
From January to July, Mercedes-Benz sold 41,583 vehicles in Korea, up 2.8 percent from 40,461 units a year earlier.
It accounted for 35 percent of the South Korean imported passenger vehicle market in the first seven months.


Nvidia Eyes $250B Guarantee for OpenAI’s Massive Ohio AI Data Center Project
Barclays Q2 Profit Beats Forecasts as Investment Banking Strength Offsets Higher Costs
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook
TeamViewer Shares Fall Despite Profit Growth as ARR and Customer Base Decline
BHP, Port Hedland Unions Fail to Reach Wage Deal as Negotiations Continue
Air Liquide Q2 Sales Growth Tops Forecast as Electronics Business Drives Strong Performance
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9%
Stellantis Sells Free2move Car-Sharing Business to Mutares to Strengthen Core Auto Strategy
Nvidia Invests $1 Billion in Naver as South Korea AI Data Center Expansion Gains Momentum
Zhongji Innolight Raises $6.8 Billion in Hong Kong IPO as AI Demand Fuels Growth
Sika Raises 2026 Sales Outlook After Strong First-Half Results Beat Expectations
Tech Stock Positioning Nears Neutral as Investor Rotation Enters Final Phase, Deutsche Bank Says
Johnson & Johnson Proposes $5.5 Billion Talc Settlement to Resolve U.S. Ovarian Cancer Lawsuits
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline
CATL Shares Jump as $5.6 Billion Buyback Signals Confidence in Long-Term Growth
Exosens H1 Profit Beats Forecasts as Defense Demand Drives Growth
Zabka Shares Drop 10% as Seven & i Abandons Investment Plans 



